<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500448</url>
  </required_header>
  <id_info>
    <org_study_id>1-Palmieri-Smith</org_study_id>
    <nct_id>NCT00500448</nct_id>
  </id_info>
  <brief_title>An Intervention of Electrical Stimulation in Osteoarthritis</brief_title>
  <official_title>The Efficacy of Neuromuscular Electrical Stimulation for Improving Quadriceps Activation in Women With Medial Tibiofemoral Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthritis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with knee osteoarthritis (OA) often have decreased thigh muscle strength. This
      muscle weakness is thought to originate from centers in the brain and spinal cord that
      restrict recruitment of fibers responsible for muscle contraction. An inability to fully
      contract muscles surrounding the knee joint impairs patients' abilities to perform activities
      of daily living (i.e. walking, climbing stairs) and may even contribute to further joint
      degeneration.

      Establishing therapies aimed at increasing muscle strength, restoring normal function, and
      possibly slowing the processes involved in the development of knee OA is essential in order
      to enhance the quality of life in the adult population plagued with this degenerative joint
      condition.

      Electrical muscle stimulation applied to the thigh is a promising therapy that has been shown
      to successfully restore muscle strength, however how long the treatment lasts and its
      influence on functional outcomes remains unknown. In order for electrical muscle stimulation
      to be of value it must result in sustained improvements in muscle strength and functional
      outcomes. Therefore, the purpose of the proposed investigation is to determine if electrical
      muscle stimulation can restore thigh muscle strength and improve functional outcomes in
      patients with knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A frequent clinical obstacle encountered in patients with knee osteoarthritis (OA) is an
      inability to achieve full voluntary activation of the quadriceps musculature. This phenomenon
      has been termed arthrogenic muscle inhibition (AMI) and is an ongoing reflex inhibition of
      musculature surrounding a joint following distension or damage to the structures of that
      joint. AMI is a limiting factor in joint rehabilitation as it restricts full muscle
      activation and therefore prevents restoration of strength. Thus, patients often participate
      in life activities deficient in strength and neuromuscular control resulting in altered lower
      extremity mechanics and potentially predisposing patients to further joint degeneration.
      Neuromuscular electrical stimulation (NMES) has been shown to be successful in reversing
      quadriceps AMI, however the duration of its effectiveness and its influence on functional
      outcomes remains elusive. Therefore, the purpose of the proposed study is to examine
      quadriceps activation and functional outcomes following a 4-week NMES protocol in patients
      with medial tibiofemoral osteoarthritis. To examine the efficacy of NMES in reversing AMI and
      improving functional outcomes, 38 subjects will be randomly assigned to either undergo a
      4-week NMES program or to undergo no therapeutic intervention. Prior to treatment and at 1,
      12, and 24 weeks following treatment, patients' quadriceps central activation ratios will be
      assessed. Additionally, subjects will undergo gait and stair climb analyses to determine if
      functional performance during these activities of daily living are improved when compared to
      the baseline assessment. Patients' perceived level of function will also be tested using the
      Western Ontario and McMasters Universities Osteoarthritis Index.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Quadriceps Central Activation Ratio at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks post-intervention</time_frame>
    <description>Knee extension Torque recorded during voluntary contraction/Knee extension torque recorded during contraction with superimposed stimulus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Quadriceps Strength at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks following the intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Disability Score at 12 Weeks</measure>
    <time_frame>baseline and 12 weeks post-intervention</time_frame>
    <description>Womac Disability Score is on a scale from 17 (no functional loss) to 85 (severe functional loss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Timed Walking Speed at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Score at 12 Weeks</measure>
    <time_frame>Baseline and 12 weeks following intervention</time_frame>
    <description>WOMAC Pain Score ranges from 5 (no pain) to 25 (worst possible pain)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Electrical Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrical Stimulation</intervention_name>
    <description>Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks</description>
    <arm_group_label>Electrical Stimulation</arm_group_label>
    <other_name>Vectra Genisys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants must be female

          -  Subjects must have radiographic osteoarthritis of grade 2 severity according to the
             Kellgren and Lawrence scale on the posterior-anterior semi-flexed view with definite
             osteophytes present in the medial and not lateral compartment.

        Exclusion Criteria:

          -  Previous adverse reaction to electrical stimulation

          -  Inability to ambulate without the use of an assistive device (i.e cane, walker)

          -  Patients who have undergone a total knee arthroplasty

          -  Patients who have torn any knee ligament (ACL, PCL, MCL, LCL)

          -  Enrollees who have a demand-type cardiac pacemaker or are pregnant

          -  History of tibial osteotomy surgery

          -  Significant peripheral or central nervous system disease

          -  Concurrent clinically active arthritis of the hip, ankle, hindfoot or midfoot in
             either limb

          -  Concurrent bilateral radiographic evidence of tibiofemoral osteoarthritis

          -  Enrollees who are concurrently undergoing physical therapy for pain or OA

          -  Enrollees who are taking Cox-2 inhibitors or are receiving corticosteroid injections

          -  Subjects will be allowed to take buffered aspirin and naproxen sodium while enrolled
             in the study

          -  Enrollees who have a body mass index of greater than 40 (morbidly obese)

          -  Enrollees who have a CAR &gt; .95 (e.g. patients whose quadriceps are uninhibited)

          -  Enrollees who have previously undergone quadriceps NMES therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riann M Palmieri-Smith, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <results_first_submitted>April 26, 2015</results_first_submitted>
  <results_first_submitted_qc>July 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2016</results_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Riann Palmieri-Smith</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Arthritis, Knee, Quadriceps, Electrical Stimulation, Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Treatment</title>
          <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
        </group>
        <group group_id="P2">
          <title>Neuromuscular Electrical Stimulation</title>
          <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Treatment</title>
          <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
        </group>
        <group group_id="B2">
          <title>Neuromuscular Electrical Stimulation</title>
          <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="2.9"/>
                    <measurement group_id="B2" value="58" spread="2.7"/>
                    <measurement group_id="B3" value="57.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163.3" spread="4.5"/>
                    <measurement group_id="B2" value="162.3" spread="7.4"/>
                    <measurement group_id="B3" value="162.8" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mass</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.8" spread="12.5"/>
                    <measurement group_id="B2" value="86.3" spread="13.6"/>
                    <measurement group_id="B3" value="87.05" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg^m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="5.1"/>
                    <measurement group_id="B2" value="32.7" spread="4.1"/>
                    <measurement group_id="B3" value="32.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Quadriceps Strength</title>
          <units>Nm/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.24" spread="0.35"/>
                    <measurement group_id="B2" value="1.29" spread="0.46"/>
                    <measurement group_id="B3" value="1.26" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Activation Ratio (CAR)</title>
          <description>Knee extensionTorque recorded during voluntary contraction/Knee extension torque recorded during contraction with superimposed stimulus</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".83" spread=".15"/>
                    <measurement group_id="B2" value=".90" spread=".08"/>
                    <measurement group_id="B3" value=".86" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WOMAC Pain Score</title>
          <description>WOMAC Pain Score ranges from 5 (no pain) to 25 (worst possible pain)</description>
          <units>units on a scale (range 5-25)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.9" spread="4.3"/>
                    <measurement group_id="B2" value="7.6" spread="2.7"/>
                    <measurement group_id="B3" value="8.25" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>WOMAC disability scale</title>
          <description>WOMAC Disability Score ranges from 17 (no loss of function) to 85 (severe loss of function)</description>
          <units>units on a scale (range 17-85)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="15.3"/>
                    <measurement group_id="B2" value="27.1" spread="12.1"/>
                    <measurement group_id="B3" value="27.95" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timed Walking speed</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.40" spread=".13"/>
                    <measurement group_id="B2" value="1.43" spread=".19"/>
                    <measurement group_id="B3" value="1.42" spread=".16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Quadriceps Central Activation Ratio at 12 Weeks</title>
        <description>Knee extension Torque recorded during voluntary contraction/Knee extension torque recorded during contraction with superimposed stimulus</description>
        <time_frame>Baseline and 12 weeks post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimulation</title>
            <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quadriceps Central Activation Ratio at 12 Weeks</title>
          <description>Knee extension Torque recorded during voluntary contraction/Knee extension torque recorded during contraction with superimposed stimulus</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.09" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-.11" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Disability Score at 12 Weeks</title>
        <description>Womac Disability Score is on a scale from 17 (no functional loss) to 85 (severe functional loss)</description>
        <time_frame>baseline and 12 weeks post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimulation</title>
            <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Disability Score at 12 Weeks</title>
          <description>Womac Disability Score is on a scale from 17 (no functional loss) to 85 (severe functional loss)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit=".59" upper_limit="9.41"/>
                    <measurement group_id="O2" value="-4.92" lower_limit="-10.89" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Timed Walking Speed at 12 Weeks</title>
        <time_frame>Baseline and 12 weeks post-intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimulation</title>
            <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Timed Walking Speed at 12 Weeks</title>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.09" upper_limit="0.17"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.13" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Score at 12 Weeks</title>
        <description>WOMAC Pain Score ranges from 5 (no pain) to 25 (worst possible pain)</description>
        <time_frame>Baseline and 12 weeks following intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimulation</title>
            <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Score at 12 Weeks</title>
          <description>WOMAC Pain Score ranges from 5 (no pain) to 25 (worst possible pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-0.26" upper_limit="3.06"/>
                    <measurement group_id="O2" value="-0.54" lower_limit="-1.83" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Quadriceps Strength at 12 Weeks</title>
        <time_frame>Baseline and 12 weeks following the intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment</title>
            <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
          </group>
          <group group_id="O2">
            <title>Neuromuscular Electrical Stimulation</title>
            <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Quadriceps Strength at 12 Weeks</title>
          <units>Nm/kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" lower_limit="-.20" upper_limit="0.49"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.50" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Treatment</title>
          <description>No treatment was delivered to this arm. Participants went about activities of daily living</description>
        </group>
        <group group_id="E2">
          <title>Neuromuscular Electrical Stimulation</title>
          <description>Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
Neuromuscular Electrical Stimulation (Vectra Genisys 4 Channel Electrotherapy System): Estim will be delivered 3 times per week for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Riann Palmieri-Smith</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346153154</phone>
      <email>riannp@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

